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I Introduction
This short report provides an update on new psychoactive 
substances (NPS) in Europe for 2014. It is based on an 
analysis of information collected by the EU Early Warning 
System, which includes the 28 Member States of the 
European Union, Turkey and Norway (see opposite). The 
report highlights recent developments, including the 
growth of the market over the past few years, as illustrated 
by seizures by law enforcement and other indicators, as 
well as the growing number of serious harms that are being 
reported as a result. The seizure data collected on NPS 
presented in this report should be regarded as minimum 
estimates due to the lack of standardised reporting in this 
area. It should be noted that these data are not directly 
comparable with the data on established illicit drugs. 
I At a glance
Over the past five years or so there has been an 
unprecedented increase in the number, type and 
availability of new psychoactive substances in Europe. 
Continuing this trend, during 2014 a total of 101 new 
substances were reported for the first time to the EU Early 
Warning System: 31 cathinones, 30 cannabinoids, 
9 phenethylamines, 5 opioids, 5 tryptamines, 
4 benzodiazepines, 4 arylalkylamines and 13 substances 
that do not conform to the aforementioned groups 
(Figure 1). This brings the total number of substances 
being monitored by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) to more than 450 
— close to double the number of substances controlled 
under the United Nations international drug control 
conventions — with more than half of these being reported 
in the last three years alone. 
Seizure data from law enforcement also confirm the 
growth and importance of this drug market. Between 2008 
and 2013 there was a seven-fold increase in the number of 
seizures reported across Europe. In 2013 almost 47 000 
seizures weighing more than 3.1 tonnes (Figures 2 and 3) 
were reported to the EU Early Warning System. Synthetic 
cannabinoids, which are sold as legal replacements for 
cannabis, accounted for the majority of these figures, with 
over 21 000 seizures weighing almost 1.6 tonnes. 
Synthetic cathinones, which are sold as legal 
replacements for stimulants such as amphetamine and 
MDMA, were the second largest group, with almost 11 000 
seizures weighing more than 1.1 tonnes. Together, 
synthetic cannabinoids and cathinones accounted for 
almost 70 % of the total number of seizures and over 85 % 
of the weight seized during 2013 (Figure 3). 
Since 1997, the EMCDDA has played a central role in 
Europe’s response to new psychoactive substances. 
Its main responsibilities in this field are to operate the 
EU Early Warning System, with its partner Europol, 
and to undertake risk assessments of new 
substances when necessary. The EU Early Warning 
System works by collecting information on the 
appearance of new substances from the 28 Member 
States, Turkey and Norway, and then monitoring them 
for signals of harm, allowing the EU to respond rapidly 
to emerging threats.
More information can be found on the EMCDDA 
website under Action on new drugs (emcdda.europa.
eu/activities/action-on-new-drugs).
EU Early Warning System
Key figures
101 new psychoactive substances reported for the first 
time in 2014 
More than 450 new psychoactive substances currently 
being monitored by the EMCDDA
46 730 seizures of new psychoactive substances 
amounting to more than 3.1 tonnes in 2013
21 495 seizures of synthetic cannabinoids amounting to 
almost 1.6 tonnes in 2013
10 657 seizures of synthetic cathinones amounting to 
more than 1.1 tonnes in 2013
Seven-fold increase in reported seizures of new 
psychoactive substances between 2008 and 2013
299 different new psychoactive substances detected 
across Europe in 2013, including many of those seen in 
previous years
16 public health alerts issued in 2014
6 risk assessments in 2014
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FIGURE 1
Number of new psychoactive substances reported to the 
EU Early Warning System, 2005–14
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FIGURE 2
Number of seizures of new psychoactive substances per 
country (map) and proportion of seizures by category of 
substance (pie chart), 2013
2 %
2 %>1 500
500–1 499
100–499
<100
   
   
   
   
   
1.
6 
to
nn
es 
                 1.1 tonnes
46 %
12 %
6 %
23 %
8 %
0.2 %
1 %
Piperazines
Benzodiazepines
Arylamines
Tryptamines
Opioids
Phenethylamines
Others
Synthetic cannabinoids
Synthetic cathinones
The growth in the market is also responsible for the 
increase in serious harms reported to the EMCDDA in 
recent years. Most of these concern non-fatal intoxications 
and deaths, but they also include broader social harms, 
such as those caused by high-risk drug users switching 
from injecting heroin to synthetic cathinones. During 2014 
serious harms that required urgent attention led to 
16 public health alerts being issued by the EMCDDA, while 
6 new substances — 25I-NBOMe, AH-7921, 
methoxetamine, MDPV, 4,4′-DMAR and MT-45 — required 
risk assessment by the EMCDDA’s Scientific Committee. 
It is likely that the growth of the market in new 
psychoactive substances will continue to pose a range of 
challenges for public health and drug policy over the next 
few years. The major drivers of many of these are the 
speed at which they appear, their open sale, and that there 
is little or no information on their effects and harms. The 
stimulant 4,4′-DMAR and the opioid MT-45 are prime 
examples of the challenges faced, and demonstrate just 
how rapidly new psychoactive substances can move from 
obscurity to infamy by causing serious harm, with 59 
deaths from these two substances reported in just one 
year. It is here that strong early warning systems can play a 
critical role in ensuring a timely response in order to 
protect public health.
FIGURE 3
Number of seizures of new psychoactive substances and 
quantity seized, 2005–13
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Note: 2009 data exclude six tonnes of ketamine seized by one country, due 
to a lack of contextual information.
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I  The market in new psychoactive substances
Until about a decade ago, only a handful of new 
psychoactive substances were reported each year in 
Europe. Most were sold on the illicit drug market, where 
they would usually be passed off as amphetamine or 
ecstasy. Some were specifically sold and sought after by 
name; others were sold as a new type of ‘ecstasy’. They 
were produced in small amounts in amateur laboratories or 
on a commercial scale in clandestine laboratories by 
organised crime groups. These new psychoactive 
substances were called ‘designer drugs’. Today, such 
drugs are still a part of Europe’s drug market. Usually they 
appear as a result of the activities of organised crime. 
Sometimes this is because these criminal groups use an 
uncontrolled precursor chemical and end up making a new 
substance either accidentally or deliberately; this has been 
the case with MDMA manufacturers making PMMA, and, 
more recently, amphetamine manufacturers making 
4-methylamphetamine (see ‘Organised crime and the new 
psychoactive substances market’). At other times, new 
psychoactive substances can emerge from this route 
because established illicit drugs are in short supply.
The emergence of the ‘legal highs’ and ‘research 
chemicals’ markets, which took off in the mid-2000s with 
the stimulants BZP and methylone (soon followed by 
mephedrone), was largely responsible for the dramatic 
growth in the market in recent years, and for catapulting 
new psychoactive substances onto the global policy 
agenda. Key to the success of both these markets was the 
fact that they were sold openly in specialised ‘head shops’ 
in towns and cities as well as via the Internet.
One of the largest groups of ‘legal high’ products is smoking 
mixtures that contain synthetic cannabinoids, which are 
intended as legal replacements to cannabis. These products 
were first popularised in Europe by the ‘Spice’ brand in the 
mid-2000s which were sold as herbal smoking mixtures 
under the guise of incense or room odorisers, but since then 
hundreds of different products have been advertised and 
sold. These products have also been responsible for a large 
number of serious harms in recent years, exemplified by 
outbreaks of intoxications requiring emergency treatment in 
hospital in the United States and Russia. 
Alongside the ‘legal highs’ and ‘research chemicals’ 
markets is a range of products containing new 
psychoactive substances that are sold under the guise of 
being ‘food supplements’ (Figure 4). These products are 
aimed not at recreational drug users but at the growing 
number of people looking to enhance their body and mind, 
allowing new psychoactive substances to reach new 
groups of consumers. One such substance that was 
detected for the first time in Europe in 2014 is adrafinil, 
which is a derivative of the medicine modafinil. This 
substance is sold as a ‘nootropic’ supplement with claims 
that it will increase energy, focus and memory.
New psychoactive substances can also emerge on the drug 
market from the diversion of medicines. In recent years this 
group has become more important as a result of the misuse 
of prescribed medicines within the EU and the growing 
illegal importation of medicines from outside the EU.
Although there is limited evidence of the involvement 
of organised crime groups in the market, it appears 
that this is an emerging threat. Perhaps in an effort to 
increase profits, clandestine synthetic production 
within the EU — normally associated with synthetic 
drugs such as amphetamine and MDMA — has been 
reported for new psychoactive substances in the 
past few years; while chemical precursors for 
producing these substances have also been seized 
by law enforcement agencies at clandestine synthetic 
drug production facilities.
Organised crime and the new 
psychoactive substances market
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FIGURE 4
The new psychoactive substances market
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Overall, the growth in the market of new psychoactive 
substances has only been possible because of the growing 
interconnectedness of the world, driven by globalisation 
and the Internet. Many of the new psychoactive 
substances that are destined for these markets are 
produced in bulk by chemical companies based in China 
and India, and shipped to Europe by air freight, where they 
are processed, packaged and then sold to consumers 
(see ‘Processing and packaging “legal highs” in Europe’). 
In 2013 the EMCDDA’s monitoring of Internet shops 
identified 651 selling ‘legal highs’ or ‘research chemicals’ 
to EU consumers. There are many more shops that sell 
food supplements that contain new psychoactive 
substances, but these are not routinely monitored by drug 
monitoring systems.
In 2014, in one EU country police dismantled a 
processing and packaging facility that was producing 
a range of ‘legal high’ products, including smoking 
mixtures, which were intended as legal replacements 
for cannabis. The seizure included large quantities of 
the synthetic cannabinoid cumyl-5F-PINACA in liquid 
form; 1 tonne of non-processed herbal material sent 
from two other EU countries and Australia; acetone, 
propylene glycol, vegetable glycerine, various aromas 
and food colourants. At this facility the synthetic 
cannabinoid was mixed with acetone, sprayed onto 
plant material and then packaged as smoking 
mixtures using the 150 kg of empty printed foil bags 
sent from China.
Processing and packaging ‘legal highs’ 
in Europe
Estimating the prevalence of use of new psychoactive 
substances is often a challenge, especially through general 
population surveys. One insight is provided by the 2014 
Flash Eurobarometer, a survey of just over 13 000 young 
adults aged 15–24 in the EU Member States, which asked 
about the use of new psychoactive substances. It found 
that 8 % of respondents had used a new psychoactive 
substance at least once, with 3 % using them in the last 
year. The highest levels of use in the last year were in 
Ireland (9 %), Spain, France (both 8 %), and Slovenia (7 %), 
with the lowest reported by Malta and Cyprus (0 %). Most 
respondents who had used new substances in the last 
year either bought them from, or were given them by, a 
friend (68 %). Just over a quarter (27 %) bought them from 
a drug dealer, while 10 % purchased them from a 
specialised shop and 3 % bought them on the Internet 
(multiple answers were possible).
While the 101 new substances reported for the first time in 
2014 to the EU Early Warning System are from a diverse 
number of chemical families with various pharmacological 
effects that span the range of drugs controlled under the 
UN International Drug Control Treaties, this report focuses 
on three groups: the synthetic cannabinoids and synthetic 
cathinones, which together are the largest group of new 
psychoactive substances that are monitored; and the 
opioids, many of which pose an especially serious risk to 
public health.
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I Synthetic cannabinoids
Synthetic cannabinoids were first detected in Europe 
towards the end of 2008. In 2014 a further 30 new 
synthetic cannabinoids were reported for the first time, 
bringing the total number reported to the EU Early Warning 
System to 134. This makes the synthetic cannabinoids the 
largest group of substances monitored by the EMCDDA, 
and reflects the overall demand for cannabis within Europe 
and the rapid pace by which manufacturers can produce 
and supply new cannabinoids in order to circumvent drug 
laws (Figure 5). The overall importance of these 
substances is also reflected in seizure data. In 2013 over 
21 000 seizures were reported, comprising more than 
FIGURE 5
Rapid replacement of synthetic cannabinoids on the European market
Substance JWH-018
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40 % of the total number of seizures for new psychoactive 
substances (Figure 3). The total weight of the seizures in 
2013 came to just under 1.6 tonnes (Figures 6 and 7); 
about 0.6 tonnes was seized as powder, often in bulk 
amounts; the remaining amount was often seized as plant 
material. These powders are used to manufacture ‘legal 
high’ products, and represent millions of doses; 10 
cannabinoids accounted for approximately 90 % of the 
total weight of powders seized in 2013, with 39 other 
cannabinoids making up the remainder. Notable seizures 
of powders in 2013 include 182 kg of AM-2201, 115 kg of 
5F-UR-144, and 114 kg of 5F-AKB48. Between 2008 and 
2013 there has been a 200-fold increase in the number of 
seizures of synthetic cannabinoids.
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FIGURE 6
Number of seizures of synthetic cannabinoids per country 
(map) and proportion of seizures by sub-category 
(pie chart), 2013
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FIGURE 7
Number of synthetic cannabinoid seizures and quantity 
seized, 2008–13
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I Synthetic cathinones
The large number of seizures of synthetic cathinones 
reflects the demand for stimulants in Europe, with many of 
them used as replacements for MDMA, amphetamine and 
cocaine. During 2014 some 31 synthetic cathinones were 
reported for the first time. This brings the total number of 
cathinones to 77, making them the second largest group of 
substances monitored by the EMCDDA. Almost 11 000 
seizures of synthetic cathinones weighing more than 
1.1 tonnes were made in Europe during 2013 (Figure 8). In 
terms of the main cathinones seized, 3-MMC (an isomer of 
the popular drug mephedrone) (341 kg), 4-MEC (201 kg), 
pentedrone (197 kg) and alpha-PVP (115 kg) accounted 
for almost 80 % of the total amount seized. Between 2008 
and 2013 there has been a 60-fold increase in the number 
of seizures of synthetic cathinones (Figure 9). 
FIGURE 8
Number of seizures of synthetic cathinones per country 
(map) and proportion of seizures by substance 
(pie chart), 2013
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FIGURE 9
Number of synthetic cathinone seizures and quantity 
seized (powders), 2005–13
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I Opioids
New opioids are of special concern for public health. This is 
because they are often highly potent and are sold as 
heroin to unsuspecting users, and thus pose a high risk of 
overdose and death. The fentanyls, for example, are a 
family of drugs that have caused hundreds of deaths in 
Europe and the United States since they first appeared as 
‘designer drugs’ sold as ‘synthetic heroin’ in California in 
the late 1970s. During 2014 three of the five opioids 
reported to the EU Early Warning System were fentanyls. 
This includes two fentanyls that were seized at a 
clandestine laboratory in Europe and acetylfentanyl which 
has been linked to more than 14 deaths in the United 
States after it was sold as heroin.
But it is not just the fentanyls that pose risks to users. More 
than 40 deaths were reported to the EMCDDA within 
months of the detection of the opioids AH-7921 and MT-45 
on the European drug market. These substances were both 
sold as ‘research chemicals’, with Internet shops based in 
Europe and China selling kilogram quantities of the drugs.
I  Monitoring and responding to serious harms
Alongside information on the appearance of new 
psychoactive substances on the market, a key function of 
the EU Early Warning System is to identify signals of 
serious harms and respond as necessary. This requires 
monitoring each of the more than 450 substances that 
have been reported so far. As the market has grown in 
recent years, the EMCDDA has also had to deal with a 
growing number of reports of serious harms, often related 
to acute toxicity leading to hospitalisation and deaths. The 
EMCDDA has responded to this challenge by working to 
strengthen the ability of the EU Early Warning System and 
its network to identify, report, understand and respond to 
such harms. One of the core activities in this respect is 
issuing public health alerts, which serve to alert the 
network on serious and urgent issues. Since 2005 the 
EMCDDA has issued 117 public health alerts, with more 
than 70 % of these issued in the last five years. During 
2014 some 16 alerts were issued. These included alerts on 
4,4′-DMAR and MT-45 after deaths within Europe were 
reported (both of these substances were risk assessed 
during 2014), and on synthetic cannabinoids such as 
5F-PB-22, ADB-PINACA and MDMB-FUBINACA after 
media monitoring by the EMCDDA identified serious harms 
in countries outside Europe.
The risk assessments conducted by the EMCDDA’s 
Scientific Committee are another core activity in 
responding to serious harms. Six risk assessments were 
conducted in 2014. These were: 25I-NBOMe, a substance 
with hallucinogenic properties that was being sold as LSD; 
AH-7921, an opioid with similar properties to morphine 
that was linked to 15 deaths over a short period of time; 
MDPV, a stimulant sold as a ‘legal high’ that was being sold 
as cocaine on the illicit market and injected by high-risk 
drug users; methoxetamine, which was sold as a legal 
replacement for the dissociative anaesthetic ketamine; 
4,4′-DMAR, a stimulant initially sold as a ‘research 
chemical’ that rapidly found its way into ecstasy tablets 
and has been linked to 31 deaths; and MT-45, an opioid 
that was sold as a ‘research chemical’ and was linked to 28 
deaths over a nine-month period.
I Summary
The data presented in this report suggest that the growth 
of the market in new psychoactive substances will 
continue to pose a range of challenges for public health 
and drug policy over the next few years. Particular 
challenges relate to the speed at which new psychoactive 
substances appear, their open sale and the lack of 
information on their effects and harms. Critically, strong 
national and regional early warning systems will continue 
to play a central role in the early detection of harms and 
help to ensure timely public health responses.
I Resources
n  Learn more about the EU Early Warning System: 
emcdda.europa.eu/ews 
n  Learn more about the EMCDDA risk assessments: 
emcdda.europa.eu/publications/risk-assessments
n  Follow the EU Early Warning System on Twitter: 
@toxicovigilance
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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